These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

215 related articles for article (PubMed ID: 32880196)

  • 21. The poly (ADP ribose) polymerase inhibitor niraparib: Management of toxicities.
    Moore KN; Mirza MR; Matulonis UA
    Gynecol Oncol; 2018 Apr; 149(1):214-220. PubMed ID: 29397193
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The role of niraparib for the treatment of ovarian cancer.
    Ethier JL; Lheureux S; Oza AM
    Future Oncol; 2018 Oct; 14(25):2565-2577. PubMed ID: 29856239
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Niraparib maintenance in frontline management of ovarian cancer: a cost effectiveness analysis.
    Barrington DA; Tubbs C; Smith HJ; Straughn JM; Senter L; Cohn DE
    Int J Gynecol Cancer; 2020 Oct; 30(10):1569-1575. PubMed ID: 32753559
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Niraparib plus bevacizumab versus niraparib alone for platinum-sensitive recurrent ovarian cancer (NSGO-AVANOVA2/ENGOT-ov24): a randomised, phase 2, superiority trial.
    Mirza MR; Åvall Lundqvist E; Birrer MJ; dePont Christensen R; Nyvang GB; Malander S; Anttila M; Werner TL; Lund B; Lindahl G; Hietanen S; Peen U; Dimoula M; Roed H; Ør Knudsen A; Staff S; Krog Vistisen A; Bjørge L; Mäenpää JU;
    Lancet Oncol; 2019 Oct; 20(10):1409-1419. PubMed ID: 31474354
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The irreversible ERBB1/2/4 inhibitor neratinib interacts with the PARP1 inhibitor niraparib to kill ovarian cancer cells.
    Booth L; Roberts JL; Samuel P; Avogadri-Connors F; Cutler RE; Lalani AS; Poklepovic A; Dent P
    Cancer Biol Ther; 2018 Jun; 19(6):525-533. PubMed ID: 29405820
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Budget impact analysis of niraparib and olaparib for maintenance treatment of platinum-sensitive, recurrent ovarian cancer in the US.
    Wu L; Zhong L
    J Med Econ; 2019 Feb; 22(2):187-195. PubMed ID: 30522378
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Randomized phase III trial on niraparib-TSR-042 (dostarlimab) versus physician's choice chemotherapy in recurrent ovarian, fallopian tube, or primary peritoneal cancer patients not candidate for platinum retreatment: NItCHE trial (MITO 33).
    Musacchio L; Salutari V; Pignata S; Braicu E; Cibula D; Colombo N; Frenel JS; Zagouri F; Carbone V; Ghizzoni V; Giolitto S; Giudice E; Perri MT; Ricci C; Scambia G; Lorusso D
    Int J Gynecol Cancer; 2021 Oct; 31(10):1369-1373. PubMed ID: 34607820
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Niraparib: A Review in First-Line Maintenance Therapy in Advanced Ovarian Cancer.
    Lee A
    Target Oncol; 2021 Nov; 16(6):839-845. PubMed ID: 34635996
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A phase 1 study of PARP-inhibitor ABT-767 in advanced solid tumors with BRCA1/2 mutations and high-grade serous ovarian, fallopian tube, or primary peritoneal cancer.
    van der Biessen DAJ; Gietema JA; de Jonge MJA; Desar IME; den Hollander MW; Dudley M; Dunbar M; Hetman R; Serpenti C; Xiong H; Mittapalli RK; Timms KM; Ansell P; Ratajczak CK; Shepherd SP; van Herpen CML
    Invest New Drugs; 2018 Oct; 36(5):828-835. PubMed ID: 29313279
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Advances in the Treatment of Ovarian Cancer Using PARP Inhibitors and the Underlying Mechanism of Resistance.
    Wang L; Wang Q; Xu Y; Cui M; Han L
    Curr Drug Targets; 2020; 21(2):167-178. PubMed ID: 31553293
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Niraparib in the maintenance treatment of advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer: safety and efficacy.
    Liu MC; Sutedja J; Tewari KS
    Expert Rev Anticancer Ther; 2021 May; 21(5):475-480. PubMed ID: 33691564
    [No Abstract]   [Full Text] [Related]  

  • 32. Predictors of long-term progression-free survival in patients with ovarian cancer treated with niraparib in the PRIMA/ENGOT-OV26/GOG-3012 study.
    Graybill WS; Pardo Búrdalo B; O'Malley DM; Vergote I; Monk BJ; Auranen A; Copeland LJ; Sabbatini R; Herzog TJ; Follana P; Pothuri B; Braicu EI; McCormick C; Yubero A; Moore RG; Vuylsteke P; Raaschou-Jensen N; York W; Hartman J; González-Martín A
    Int J Gynecol Cancer; 2024 Jul; 34(7):1041-1050. PubMed ID: 38950925
    [TBL] [Abstract][Full Text] [Related]  

  • 33. PARP inhibitors in ovarian cancer: Sensitivity prediction and resistance mechanisms.
    Jiang X; Li X; Li W; Bai H; Zhang Z
    J Cell Mol Med; 2019 Apr; 23(4):2303-2313. PubMed ID: 30672100
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Molecular signatures of BRCAness analysis identifies PARP inhibitor Niraparib as a novel targeted therapeutic strategy for soft tissue Sarcomas.
    Li H; Tu J; Zhao Z; Chen L; Qu Y; Li H; Yao H; Wang X; Lee DF; Shen J; Wen L; Huang G; Xie X
    Theranostics; 2020; 10(21):9477-9494. PubMed ID: 32863940
    [No Abstract]   [Full Text] [Related]  

  • 35. Efficacy and Safety of Niraparib as First-Line Maintenance Treatment for Patients with Advanced Ovarian Cancer: Real-World Data from a Multicenter Study in China.
    Zhao M; Qiu S; Wu X; Miao P; Jiang Z; Zhu T; Xu X; Zhu Y; Zhang B; Yuan D; Zhang Y; Sun W; He A; Zhao M; Hou W; Zhang Y; Shao Z; Jia M; Li M; Chen J; Xu J; Chen B; Zhou Y; Shen Y
    Target Oncol; 2023 Nov; 18(6):869-883. PubMed ID: 37847485
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Avatrombopag Optimizes Response to Niraparib by Managing Thrombocytopenia Associated with Poly-ADP Ribose Polymerase (PARP) Inhibition in Ovarian Cancer and Breast Cancer: A Case Series.
    Gabrail N; Smith C
    Am J Case Rep; 2020 Nov; 21():e927008. PubMed ID: 33191394
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Real-world adverse events with niraparib 200 mg/day maintenance therapy in ovarian cancer: a retrospective study.
    Gallagher JR; Heap KJ; Carroll S; Travers K; Harrow B; Westin SN
    Future Oncol; 2019 Dec; 15(36):4197-4206. PubMed ID: 31707856
    [No Abstract]   [Full Text] [Related]  

  • 38. PARP inhibitors combined with ionizing radiation induce different effects in melanoma cells and healthy fibroblasts.
    Weigert V; Jost T; Hecht M; Knippertz I; Heinzerling L; Fietkau R; Distel LV
    BMC Cancer; 2020 Aug; 20(1):775. PubMed ID: 32811446
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [New drug approval: Olaparib and niraparib - first line in ovarian cancer].
    Delaye M; Rodrigues M
    Bull Cancer; 2021 Apr; 108(4):350-351. PubMed ID: 33641880
    [No Abstract]   [Full Text] [Related]  

  • 40. Phase 2 single-arm study on the efficacy and safety of niraparib in Japanese patients with heavily pretreated, homologous recombination-deficient ovarian cancer.
    Okamoto A; Kondo E; Nakamura T; Yanagida S; Hamanishi J; Harano K; Hasegawa K; Hirasawa T; Hori K; Komiyama S; Matsuura M; Nakai H; Nakamura H; Sakata J; Tabata T; Takehara K; Takekuma M; Yokoyama Y; Kase Y; Sumino S; Soeda J; Suri A; Aoki D; Sugiyama T
    J Gynecol Oncol; 2021 Mar; 32(2):e16. PubMed ID: 33327047
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.